Neurovalens receives second FDA approval

April 16, 2024

In November 2023, the team received FDA medical device approval for their Modius Sleep device which means that it is now considered a Class II medical device that can be prescribed in the US as a treatment for chronic insomnia. In another exciting advancement, today the team has announced that they have received FDA approval for their stress reduction device.

Investment Team

Meet the team

We’re pretty sparing with our email comms, but when there are interesting and relevant things happening it’s great to share. If you’d like to receive updates and hear more about what is happening with ACF Investors and the portfolio then please sign up here.

Website by James Dowen Web Designer Web Developer Web design london